A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting

Table 2 Participants characteristics

Study	n	Mean Age	Male (%)	Mean EF (%)	Mean NYHA Class	Triple Vessel Disease (%)	≥1 anti-anginal medication (%)	Previous MI (%)	DM (%)	Renal Disease (%)	Prior use of Allopurinol
Emerit et al. (1988)	14	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Rashid et al. (1991)	90	62	76	> 50^a	2.3	NR	NR	NR	NR^e	NR^e	NR
Coghlan et al. (1994)	50	58	84	63	NR^b	92	NR^d	34	14	NR	NR
Taggart et al. (1994)	20	60	100	53	NR	NR	NR	NR	NR	0	0
Castelli et al. (1995)	33	61	94	64	3	NR	NR	79	NR	NR	NR
Gimpel et al. (1995)	22	59	77	NR	NR^c	NR	100	50	NR	NR	NR

EF ejection fraction, NYHA New York Heart Association, MI myocardial infarction, DM diabetes mellitus; NR, not reported
The number of decimal places reported in the included studies varied. Data has been rounded up to whole where appropriate
^aEjection fraction > 50% in 71% of the allopurinol group and 67% of the control group
^bMean NYHA class not specified. 80% of (n) with NYHA class 3 or 4
^cMean NYHA class not specified. 100% of (n) with NYHA class 3 or 4
^dReports nitrate use in 10%, beta-blocker use in 46% and calcium channel blocker use in 44%
^ePrevalence of ‘other organ disease/dysfunction’ reported to be zero. It was unclear whether this included previous cerebrovascular disease, DM, renal disease and/or PAD

ISSN: 1471-2261